62150-47-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-pyridine-2-carboxylic acid ethyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of novel drugs with potential therapeutic applications.
Used in Inhibitor Development:
In the field of biochemistry and drug discovery, 4-Bromo-pyridine-2-carboxylic acid ethyl ester is used as a starting material for the development of inhibitors targeting murine adipose triglyceride lipase (mATGL). This enzyme plays a crucial role in the regulation of lipid metabolism, and its inhibition can have significant implications in the treatment of obesity and related metabolic disorders.
By leveraging the unique structural features of 4-Bromo-pyridine-2-carboxylic acid ethyl ester, researchers can design and synthesize potent and selective inhibitors that can modulate the activity of mATGL, potentially leading to the development of new therapeutic strategies for obesity and other metabolic diseases.

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 19524-06-2 4-bromopyridine hydrochloride 
• 62150-45-2 4-bromo-2-cyanopyridine 
• 14248-50-1 4-bromopyridine-1-oxide 
• 1120-87-2 4-bromopyridin 
• 64-17-5 ethanol 
• 30766-03-1 4-bromo-2-picolinic acid 

Downstream Products

• 62150-48-5 4-bromopicolinohydrazide 
• 131747-45-0 4-bromo-2-(hydroxymethyl)pyridine 
• 477252-20-3 2-(4-bromopyridin-2-yl)propan-2-ol 
• 62150-46-3 4-bromopyridine-2-carboxamide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 1,3,4-oxadiazole fused pyridine derivatives as antibacterial and antifungal agents

A series of novel 1,3,4-oxadiazole fused pyridine derivatives were synthesized 11a–11f and their structures confirmed by IR, 1H NMR and Mass spectral data. The compounds were evaluated for their antibacterial and antifungal activities against Gram negative and positive bacterial strains including Escherichia coli (MTCC 443), K. Pneumoniae (MTCC 109), S. Aureus (MTCC 96), B. Subtilis (MTCC 441) and Sclerotium rolfsii, Macrophomina phaseolina. Compounds 11d, 11e, and 11f demonstrated high antibacterial activity.

TGF-beta receptor inhibitor

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compound shown as the formula (I) of the present invention is useful as a TGF-beta receptor inhibitor, particularly a TGF beta RI inhibitor, for example, in the prevention or treatment of various TGF beta RI (ALK5) mediated related diseases.

Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL)

High serum fatty acid (FA) levels are causally linked to the development of insulin resistance, which eventually progresses to type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin resistance and NAFLD. In this article, we report about structure–activity relationship (SAR) studies of small molecule inhibitors of murine ATGL which led to the development of Atglistatin. Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target.

Synthesis method of 2-pyridylaldehyde derivative

The invention relates to the field of medical intermediates, in particular to a synthesis method of 2-pyridylaldehyde derivative. A synthesis path shown in the formula 1 is adopted, wherein X can be Cl or Br or CF3. Cheap starting raw materials are adopted, the use of hazardous materials which have large toxicity and are easily explosive is avoided, the cost of the product is greatly lowered, popularization and industrialized production are facilitated, and the synthesis method has the advantages of being low in cost, easy to operate, high in yield, easy to industrialize and the like. The formula 1 is shown in the description.

2 - Amino - 4 - bromo pyridine synthesis method

The invention relates to the field of medical intermediate synthesis, in particular to a synthetic method of 2-amino-4-bromopyridine, and provides a preparation method of 2-amino-4-bromopyridine. The preparation method comprises the following steps: (1) esterification reaction: esterifying 4-bromopyridinium chloride to obtain a 4-bromopyridine-2-ethyl formate crude product; (2) ammoniation reaction: ammonifying the 4-bromopyridine-2-ethyl formate crude product into 4-bromopyridine-2-formamide; (3) Hofmann degradation reaction: conducting Hofmann degradation on 4-bromopyridine-2-formamide to obtain 2-amino-4-bromopyridine, wherein the synthetic route is shown in the formula I. The synthetic method provided by the invention has the advantages that the raw material cost is low; the yield is high; the reactions and the operation are simple; the three waste treatment is convenient; industrialization can be realized easily.